The Latest

  • COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Board of Directors
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
  • Our Clinical Trials
    • CNP-106 Myasthenia Gravis
  • Publications & Media
    • Press Releases
    • Publications
  • Careers

Uncategorized

COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

… [Read more...] about COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

… [Read more...] about COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures

COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer

… [Read more...] about COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer

COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director

… [Read more...] about COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director

  • « Go to Previous Page
  • Page 1
  • Page 2

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2025

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top